Optimal antihypertensive therapy in patients with the metabolic syndrome
This article has no abstract so we have provided the first paragraph of the full text.
To determine the optimal antihypertensive therapy for patients with the metabolic syndrome (MetS), Black et al. conducted a subgroup analysis of the ALLHAT study, comparing metabolic, cardiovascular and renal outcomes in individuals on thiazide-like diuretics to the outcomes in patients on angiotensin-converting enzyme inhibitors or calcium-channel blockers.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
